Group One Trading’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.05M | Sell |
584,200
-589,200
| -50% | -$1.88M | ﹤0.01% | 2049 |
|
|
2025
Q4 | $3.2M | Buy |
1,173,400
+462,800
| +65% | +$1.07M | 0.01% | 1856 |
|
|
2025
Q3 | $1.54M | Buy |
710,600
+166,400
| +31% | +$393K | ﹤0.01% | 2577 |
|
|
2025
Q2 | $936K | Sell |
544,200
-4,300
| -0.8% | -$10.7K | ﹤0.01% | 2832 |
|
|
2025
Q1 | $1.83M | Sell |
548,500
-274,400
| -33% | -$1.42M | 0.01% | 1903 |
|
|
2024
Q4 | $6.09M | Buy |
822,900
+177,600
| +28% | +$1.65M | 0.01% | 1019 |
|
|
2024
Q3 | $6.06M | Buy |
645,300
+319,600
| +98% | +$3.03M | 0.02% | 891 |
|
|
2024
Q2 | $2.61M | Sell |
325,700
-1,163,400
| -78% | -$12.5M | 0.01% | 1233 |
|
|
2024
Q1 | $22.1M | Buy |
1,489,100
+433,200
| +41% | +$5.04M | 0.08% | 164 |
|
|
2023
Q4 | $8.58M | Buy |
1,055,900
+244,200
| +30% | +$1.28M | 0.02% | 782 |
|
|
2023
Q3 | $3.69M | Buy |
811,700
+347,400
| +75% | +$2.27M | 0.01% | 1138 |
|
|
2023
Q2 | $3.27M | Buy |
464,300
+173,500
| +60% | +$1.24M | 0.01% | 1300 |
|
|
2023
Q1 | $1.78M | Sell |
290,800
-254,000
| -47% | -$1.75M | 0.01% | 1640 |
|
|
2022
Q4 | $3.48M | Buy |
544,800
+312,400
| +134% | +$2.44M | 0.01% | 1390 |
|
|
2022
Q3 | $2.23M | Sell |
232,400
-67,000
| -22% | -$773K | ﹤0.01% | 1820 |
|
|
2022
Q2 | $3.31M | Sell |
299,400
-105,800
| -26% | -$1.39M | 0.01% | 1611 |
|
|
2022
Q1 | $6.75M | Buy |
405,200
+171,800
| +74% | +$2.66M | 0.01% | 1299 |
|
|
2021
Q4 | $4.46M | Buy |
233,400
+149,600
| +179% | +$3.29M | ﹤0.01% | 1808 |
|
|
2021
Q3 | $2.07M | Sell |
83,800
-515,600
| -86% | -$12.1M | ﹤0.01% | 2619 |
|
|
2021
Q2 | $15.6M | Buy |
599,400
+475,800
| +385% | +$12.4M | 0.02% | 788 |
|
|
2021
Q1 | $3.91M | Sell |
123,600
-73,700
| -37% | -$3.05M | 0.01% | 1776 |
|
|
2020
Q4 | $9.15M | Buy |
197,300
+106,200
| +117% | +$4.22M | 0.02% | 858 |
|
|
2020
Q3 | $3M | Sell |
91,100
-233,400
| -72% | -$7.16M | 0.01% | 1273 |
|
|
2020
Q2 | $8.91M | Buy |
324,500
+16,000
| +5% | +$526K | 0.04% | 501 |
|
|
2020
Q1 | $9.23M | Buy |
308,500
+166,100
| +117% | +$4.4M | 0.07% | 287 |
|
|
2019
Q4 | $3.94M | Sell |
142,400
-74,900
| -34% | -$1.7M | 0.03% | 824 |
|
|
2019
Q3 | $3.96M | Buy |
217,300
+195,800
| +911% | +$4.33M | 0.03% | 726 |
|
|
2019
Q2 | $527K | Buy |
21,500
+11,500
| +115% | +$173K | ﹤0.01% | 2089 |
|
|
2019
Q1 | $95K | Sell |
10,000
-200
| -2% | -$1.94K | ﹤0.01% | 3207 |
|
|
2018
Q4 | $90K | Sell |
10,200
-13,700
| -57% | -$132K | ﹤0.01% | 3230 |
|
|
2018
Q3 | $269K | Buy |
23,900
+15,000
| +169% | +$213K | ﹤0.01% | 2792 |
|
|
2018
Q2 | $114K | Sell |
8,900
-29,200
| -77% | -$427K | ﹤0.01% | 3470 |
|
|
2018
Q1 | $644K | Buy |
38,100
+6,400
| +20% | +$96.9K | 0.01% | 1851 |
|
|
2017
Q4 | $254K | Buy |
+31,700
| New | +$255K | ﹤0.01% | 2776 |
|
|
2017
Q3 | – | Sell |
-24,000
| Closed | -$176K | – | 4977 |
|
|
2017
Q2 | $176K | Buy |
+24,000
| New | +$153K | ﹤0.01% | 2730 |
|
|
2016
Q4 | – | Sell |
-6,500
| Closed | -$54K | – | 4605 |
|
|
2016
Q3 | $54K | Sell |
6,500
-13,500
| -68% | -$114K | ﹤0.01% | 3310 |
|
|
2016
Q2 | $162K | Sell |
20,000
-41,300
| -67% | -$259K | ﹤0.01% | 2549 |
|
|
2016
Q1 | $311K | Sell |
61,300
-52,500
| -46% | -$287K | ﹤0.01% | 2024 |
|
|
2015
Q4 | $879K | Buy |
113,800
+95,900
| +536% | +$665K | 0.01% | 1394 |
|
|
2015
Q3 | $103K | Buy |
+17,900
| New | +$139K | ﹤0.01% | 3017 |
|
Other funds holding IOVA
MFM
VCM
VPM
ICM
Group One Trading's IOVA Position: Q1 2026 in Review
Group One Trading increased its Iovance Biotherapeutics (IOVA) stake by 253% in Q1 2026, buying an estimated $1.37M and bringing the position to 595,756 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2035.
Group One Trading first reported a position in IOVA in Q2 2015 and has held it in 33 quarters since. The position peaked at $12.6M in Q4 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.
- Group One Trading held 595,756 shares of Iovance Biotherapeutics worth $2.09M as of Q1 2026.
- Group One Trading bought 427,079 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.37M.
- Iovance Biotherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2035 holding.
- Group One Trading first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 33 quarters since.
- Group One Trading's Iovance Biotherapeutics position peaked at $12.6M in Q4 2024.
- 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.